Skip to Main Content

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata (BRAVE-AA1)

Conditions

Diseases of the Integumentary System | Men's Health | Women's Health

Phase II-III

What is the purpose of this trial?

Brief Summary:

This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata.

  • Trial with
    Eli Lilly and Company
  • Start Date
    01/02/2019
  • End Date
    12/30/2018
Trial Image

For more information about this study, contact:

Rebecca Chawarski

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    02/06/2019
  • Study HIC
    #2000023903